New Gastro Guidelines; Best First-Line Option in UC? Late-Stage Trial Win for Hep D

This gastroenterology/hepatology digest covers new AGA and European guidelines on MASLD, alcohol-associated liver disease, cancer surveillance, and serrated polyposis syndrome, alongside several new trial and cohort findings. In ulcerative colitis, a 5-year analysis found first-line vedolizumab outperformed TNF inhibitors on corticosteroid-free time, while in TNF-exposed patients upadacitinib showed better effectiveness than vedolizumab but with more adverse events. Mirum Pharmaceuticals reported that its phase III AZURE-1 trial of brelovitug met its primary endpoint for chronic hepatitis delta virus, achieving virologic response and ALT normalization. Other items include phase II data on tipelukast for MASLD-related hypertriglyceridemia, a pain-management review for chronic pancreatitis, probiotic benefits for preterm infants, capsule endoscopy follow-up data on Crohn's disease, microbiome-cirrhosis hospitalization links, and transplant prophylaxis findings.